Relmada Therapeutics, Inc. RLMD Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfShortTermInvestments.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s investment proceeds?
- Relmada Therapeutics, Inc. (RLMD) reported investment proceeds of $14.29M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s investment proceeds changed year-over-year?
- Relmada Therapeutics, Inc.'s investment proceeds decreased by 9.8% year-over-year, from $15.85M to $14.29M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s investment proceeds has grown at a -32.2% compound annual growth rate (CAGR), from $168.86M to $35.69M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.